title: Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers.
abstract: OBJECTIVE
  The pathological state of the prostate may be reflected by serum proteome in a man. We hypothesized that biomarkers are present in preoperative serum, which may be used to predict the probability of biochemical recurrence following radical prostatectomy.
  
  
  METHODS
  Mass spectrometry analysis was used to compare 52 men who experienced biochemical recurrence with 52 who remained biochemical recurrence-free for approximately 5 years after radical retropubic prostatectomy. A total of 30 matched pairs of recurrent and nonrecurrent serum samples were randomly selected as a training set for biomarker discovery and model development. Selected mass spectrometry peaks were combined with pre-radical retropubic prostatectomy prostate specific antigen in a multivariate algorithm to predict recurrence. The algorithm was evaluated using the remaining 22 recurrent and 22 nonrecurrent subjects as test samples. Protein identities of the selected mass spectrometry peaks were investigated.
  
  
  RESULTS
  Two serum biomarkers for recurrence, P1 and P2, were combined with preoperative prostate specific antigen to predict biochemical recurrence. The ROC AUC for prostate specific antigen and the predicted outcome was 0.606 and 0.691 in the testing data, respectively. Using a single cutoff the samples were divided into 2 groups that were predictive of biochemical recurrence (p = 0.026). In contrast, preoperative prostate specific antigen did not differ between recurrent and nonrecurrent cases (Wilcoxon matched pairs test p = 0.07). The protein identity of P1 was determined to be a truncated form of C4a (C4a des-Arg). Preliminary data indicated that P2 was an N-terminal fragment of protein C inhibitor.
  
  
  CONCLUSIONS
  In the current study population, which was matched on Gleason score and TNM staging, pre-radical retropubic prostatectomy prostate specific antigen retained no independent power to predict recurrence. However, by adding 2 proteomic biomarkers to preoperative prostate specific antigen the combined model demonstrated statistically significant value for predicting prostate cancer recurrence in men who underwent radical retropubic prostatectomy.
authors.affiliation: Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
authors.forename: C Nicole
authors.initials: CN
authors.lastname: Rosenzweig
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zhang
authors.forename: Xiaer
authors.initials: X
authors.lastname: Sun
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Sokoll
authors.forename: Katherine
authors.initials: K
authors.lastname: Osborne
authors.forename: Alan W
authors.initials: AW
authors.lastname: Partin
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Chan
mesh_terms: D015415:Biomarkers / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood*; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000097:blood*; D040901:Proteomics
chemical_list: D015415:Biomarkers